Illumina Inc. announced on Tuesday that its board has approved a second spinoff of Grail, the cancer detection company it reacquired in 2020. This decision follows a contentious period marked by criticism from activist investor Carl Icahn and an order from European authorities mandating the disposal of the asset. This move is seen as a significant step in complying with regulatory directives. For further details on this development, visit the original Law360 article.